Promoted content

In this section, you will find content donated by our Industry Partners working in the field of Interventional Cardiovascular Disease. This content is considered to be of educational value and is not intended as advertising. Publication on this website does not equal endorsement. Discover the promoted content ...

Filter By

3 results

ACURATE neo™ Aortic Valve System shows safety & efficacy results comparable to SAPIEN 3

Multi-centre propensity-matched comparison study1 between ACURATE neo Aortic Valve System and Edwards SAPIEN 3 Transcatheter Heart Valve, published in October’s edition of the Journal of the American College of Cardiology (JACC) shows comparable procedural outcomes:

Observational, propensity-matched multicenter comparison of ACURATE neo and SAPIEN 3 from 3 high volume centers in Germany (DHZ Munich, UK Regensburg, Kerckhoff Klinikum Bad Nauheim)1,121 consecutive patients between Jan. 2014 and Jan. 2016 with symptomatic, severe stenosis of the native aortic valve treated with transfemoral TAVI using ACURATE neo (n = 311) or SAPIEN 3 (n = 810)To increase statistical power, a 1-to-2 nearest neighbor matching was used to identify 2 control cases treated with SAPIEN 3 (n = 622) for each case treated with ACURATE neo (n = 311)Endpoints: device failure and early safety composite endpoint at 30 days according to VARC-2 criteria

View full JACC publication

Biodegradable polymer Everolimus-eluting SYNERGY stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial

Elderly patients regularly receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of double antiplatelet therapy (DAPT). The aim of this study was to compare outcomes between these two types of stents with a short duration of DAPT in such patients. Study concluded that  BP-EES stent and a short duration of DAPT is better than BMS and a similar duration of DAPT with respect to the occurrence of all-cause mortality, myocardial infarction, stroke, and ischaemia-driven target lesion revascularisation.

SOURCE 3 post-approval registry—One-year outcomes in 1,946 TAVI patients with a 3rd generation balloon transcatheter heart valve

 
Speaker: O. Wendler

At 1 year, patients treated via the transfemoral access route had a high survival rate (88.2 percent) and a low disabling stroke rate (1.1 percent).Patients experienced a low rate (2.7 percent) of moderate paravalvular leak and no severe paravalvular leak.